Bio-Rad Laboratories Inc - Class B

Research Bio-Rad Laboratories Inc - Class B (BIO-B) on Bullrun: market cap USD 7.99B, P/E 49.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 7.99B; P/E is 49.8.

Peer valuation comparison

Latest P/E is 49.75x versus a Healthcare sector median of 24.46x (103.4% above).

Latest P/E is 49.75x versus a United States median of 24.87x (100.1% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 2.58BUSD 759.90MUSD 374.60M51.9%27.85USD 529.80MUSD 1.20BUSD 7.45B
FY2024USD 2.57B-USD 1.84BUSD 289.60M53.7%-65.36USD 488.10MUSD 1.20BUSD 6.57B
FY2023USD 2.67B-USD 637.30MUSD 218.20M53.4%-21.82USD 403.80MUSD 1.20BUSD 8.74B
FY2022USD 2.80B-USD 3.63BUSD 81.60M55.9%-121.79USD 434.20MUSD 1.20BUSD 9.62B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-07-13USD 7.99B49.8n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 USD.

About Bio-Rad Laboratories Inc - Class B

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Bio-Rad Laboratories Inc - Class B's market cap?

Bio-Rad Laboratories Inc - Class B's market capitalization is USD 7.99B.

What is Bio-Rad Laboratories Inc - Class B's P/E ratio?

Bio-Rad Laboratories Inc - Class B's price-to-earnings (P/E) ratio is 49.8.

What does Bio-Rad Laboratories Inc - Class B do?

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.